Language

English

Publication Date

8-23-2025

Journal

Communications Biology

DOI

10.1038/s42003-025-08662-z

PMID

40847090

PMCID

PMC12373792

PubMedCentral® Posted Date

8-23-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Encapsulating peritoneal sclerosis (EPS) is a life-threatening fibrotic condition characterized by severe abdominal adhesions, chronic inflammation, and significant morbidity. The lack of effective treatments for EPS stems from a limited understanding of its underlying mechanisms. In this study, we developed a modified mouse model of PD-induced EPS and investigated the role of the STING signaling pathway in disease progression. Our findings reveal that STING activation in peritoneal mesothelial cells significantly increases the secretion of the macrophage chemokine CCL2, leading to enhanced macrophage infiltration and the formation of pathological adhesions. Notably, pharmacological inhibition of STING using the inhibitor H151 effectively reduced macrophage infiltration and fibrosis, demonstrating its therapeutic potential in alleviating EPS. These results identify the STING pathway as a critical mediator of EPS pathogenesis and suggest that STING inhibitors could offer a promising therapeutic strategy to prevent or reverse EPS, particularly in clinical settings such as peritoneal dialysis.

Keywords

Peritoneal Fibrosis, Animals, Mice, Macrophages, Disease Models, Animal, Membrane Proteins, Signal Transduction, Mice, Inbred C57BL, Cell Adhesion, Chemokine CCL2, Male, Peritoneal Dialysis, Kidney diseases, Peritoneal dialysis

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.